MON-LB9 Cyclic Progesterone Therapy in Androgenic Polycystic Ovary Syndrome (PCOS) - Person-Related 6-Month Experience Changes

Endometrial cancer(1) and oligomenorrhea(2) are common risks for women living with androgenic PCOS (WLWP); cyclic progesterone therapy could prevent both. Cyclic oral micronized progesterone therapy (Cyclic OMP; 300 mg at hs/14 days/cycle) also corrects the neuroendocrine origins of PCOS(3). Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirin, Sonia, Murray, Faye, Hajjaran, Maryam, Goshtasebi, Azita, Kalidasan, Dharani, Prior, Jerilynn C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Reproductive Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208794/
http://dx.doi.org/10.1210/jendso/bvaa046.2332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208794/
http://dx.doi.org/10.1210/jendso/bvaa046.2332

Ejemplares similares